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Abstract
Increase in the generation and deposition of amyloid-b (Ab) plays a central role in the development of Alzheimer’s Disease
(AD). Elevation of the activity of c-secretase, a key enzyme required for the generation for Ab, can thus be a potential risk
factor in AD. However, it is not known whether c-secretase can be upregulated in vivo. While in vitro studies showed that
expression of all four components of c-secretase (Nicastrin, Presenilin, Pen-2 and Aph-1) are required for upregulation of c-
secretase, it remains to be established as to whether this is true in vivo. To investigate whether overexpressing a single
component of the c-secretase complex is sufficient to elevate its level and activity in the brain, we analyzed transgenic mice
expressing either wild type or familial AD (fAD) associated mutant PS1. In contrast to cell culture studies, overexpression of
either wild type or mutant PS1 is sufficient to increase levels of Nicastrin and Pen-2, and elevate the level of active c-
secretase complex, enzymatic activity of c-secretase and the deposition of Ab in brains of mice. Importantly, c-secretase
comprised of mutant PS1 is less active than that of wild type PS1-containing c-secretase; however, c-secretase comprised of
mutant PS1 cleaves at the Ab42 site of APP-CTFs more efficiently than at the Ab40 site, resulting in greater accumulation of
Ab deposits in the brain. Our data suggest that whereas fAD-linked PS1 mutants cause early onset disease, upregulation of
PS1/c-secretase activity may be a risk factor for late onset sporadic AD.
Citation: Li T, Li Y-M, Ahn K, Price DL, Sisodia SS, et al. (2011) Increased Expression of PS1 Is Sufficient to Elevate the Level and Activity of c-Secretase In Vivo. PLoS
ONE 6(11): e28179. doi:10.1371/journal.pone.0028179
Editor: Koichi M. Iijima, Thomas Jefferson University, United States of America
Received June 3, 2011; Accepted November 2, 2011; Published November 29, 2011
Copyright:  2011 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from National Institute of Neurological Disorders and Stroke (NINDS) (R01 NS45150, and P01 NS047308 to PCW), the
National Institute on Aging (NIA) (P50 AG05146 to DLP), MetLife Foundation (to PCW), Frederic J. Pelda Alzheimer’s Research Fund (to Division of Neuropathology
at Johns Hopkins) (to TL), Adler Foundation (to TL) and Ellison Medical Foundation (to TL). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tli1@jhmi.edu
Introduction
Alzheimer’s disease (AD), the most common form of dementia
occurring in the elderly, is a progressive neurodegenerative disease
characterized pathologically by neuritic (or senile) amyloid plaques
and neurofibrillary tangles in the brain [1]. Neuritic plaques are
mainly consists of amyloid-b peptides (Ab) that are generated pro-
teolytically from amyloid-b precursor protein (APP) by the sequential
cleavage of b-a n dc-secretase. Current genetic and epidemiological
studies support the ‘‘amyloid cascade hypothesis’’ of AD [2], which
posits that genetic or environmental factors cause abnormal
accumulation of dimers, oligomers or higher order assemblies of
Ab, which are neurotoxic and initiate a cascade of events eventually
leading to synaptic and neuronal dysfunction and death in cases of
AD. This view is supported by the genetic studies in which missense
mutations in APP [3–5], PS1 and PS2 [6–9], and duplications of APP
[10] have been linked to cases of early onset familial AD (fAD). All of
these mutations either increase the generation of Ab or increase
relative levels of Ab42, the more toxic form of Ab.A so n l y
symptomatic therapies are currently available, mechanism-based
disease modifying therapy remains a major unmet need for AD[11].
FAD accounts for ,5% of total AD cases, whereas .90% of
individuals with AD manifest as late onset sporadic form of AD
(sAD). While the genetic risk factors that contribute to Ab
amyloidosis in sAD cases are less clear, putative sporadic cases are
influenced by a variety of susceptibility genes and possibly other
less well-defined factors [12]. One gene that has been consistently
replicated as a major dose-dependent risk factor in a large number
of studies across many ethnic groups is the Apoe4 allele of the
apolipoprotein E gene (chromosome 19q13), which has been
hypothesized to influence Ab metabolism, Ab aggregation/
degradation/clearance [13–15]. Recent research has identified
gene variants encoding ubiquilin1 (UBQLN1) [16] and sortilin1
(SORL1) [17] as risk factors, and GWAS approaches have
identified a number of variants (CLU, PICALM and CRI)
associated with AD [18,19], which may also contribute to
abnormal APP processing and Ab accumulation. Therefore, it
has been widely accepted that both sporadic and familial AD share
the same underlying disease mechanism by promoting the
accumulation of Ab in the brain.
As enzymes required for the generation of Ab, increase of b-
and c-secretase activities in the brain represent potential risks for
the development of AD. While it has been reported that higher
levels of BACE1 are associated with increased risk for AD [20,21],
less information is available regarding the relationships between
altered levels of c-secretase and risk of development of AD.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28179Moreover, the idea that c-secretase is a risk factor for AD is
challenged by the assumption that upregulation of c-secretase is
difficult to achieve. Although PS alone exhibits c-secretase activity,
each component of the c-secretase complex, PS, Nct, APH-1 and
PEN-2, is absolutely required for c-secretase activity in vivo [22].
While the mechanism of assembly of c-secretase complex is still
not completely understood, the accumulation of c-secretase
appears to be tightly controlled. A simple model of c-secretase
assembly invokes initially the formation of a relatively stable pre-
complex comprised of Nct and Aph-1 [23], and the subsequent
associations of PS and PEN-2 with this pre-complex lead to the
formation of the mature c-secretase complex. The mature c-
secretase complex is characterized by the post-translational
modifications of various subunits, while the enzyme complex is
transported en route to the plasma membrane. Evidence indicates
that some components of c-secretase complex, such as PS, are not
stable unless they are associated with other components to form
the pre- or mature c-secretase complex [23–26]. Therefore, the
downregulation of c-secretase can be achieved by reducing anyone
of the four essential components of c-secretase.
In contrast, overexpression of any one member has little effect
on the levels of other components or the overall c-secretase activity
in cell culture systems [27–31]. In fact, overexpression of even any
combination of three proteins is still not sufficient to increase the
activity of c-secretase; elevation in c-secretase activity can only be
achieved by overexpressing all four proteins [32]. These
observations led to the assumption that the upregulation of c-
secretase is unlikely to occur in the brain since upregulation of all
four components of c-secretase is necessary to increase the level of
c-secretase. However, this assumption is based on in vitro cell
culture studies and has not been thoroughly tested in vivo.
In this report, we document that, in contrast to the observations
derived from cell culture studies, increased expression of PS1 alone
significantly increased the level and activity of c-secretase and the
Ab burden in the brain, suggesting the possibility that elevation of
c-secretase may be a risk factor in AD.
Results
While previous efforts demonstrated that increased expression
of all four components of c-secretase is required to upregulate its
enzymatic activity in cultured cells, it remains to be established
whether overexpression of all four components is necessary to
increase the level of c-secretase in vivo. To determine whether
overexpression of a single component of the c-secretase is sufficient
to elevate its level and activity in the brain, we analyzed transgenic
mice expressing human wild type PS1 under the control of mouse
PrP promoter [33]. Initial protein blot analysis of levels of PS1 in
brains of PS1 transgenic mice using antibodies specific to C-
terminal fragments of PS1 (one of two processed fragments of PS1
associated with the mature c-secretase complex), revealed
overexpression of human PS1 protein (Fig. 1A). To confirm the
‘‘replacement effect’’ of the exogenous human PS1, we assessed
the level of endogenous PS by analyzing the level of PS2 using
antiserum recognizing the C-terminal fragment of PS2 (PS2-CTF).
As expected, the level of PS2-CTF was significantly reduced in
brains of PS1 transgenic mice as compared to that of controls
(Fig. 1A and 1B). Since anti-PS1 antibody can recognize the
human and mouse PS1 with higher affinity, levels of c-secretase
complex in PS1 transgenic mice cannot be evaluated by western
blot using antibodies against PS1. To assess the levels of c-
secretase complex, we analyzed the endogenous protein levels of
Nct and PEN2, two key components of c-secretase complex in
brains of PS1 transgenic mice. Interestingly, protein levels of PEN2
was significantly increased (,200%, p,0.005) in PS1 transgenic
mice as compared to that of wild type mice (Fig. 1A and 1B).
Consistent with this finding, we also observed an increase of
endogenous Nct in PS1 transgenic mice as compared to that of
wild type mice (Fig. 1A and 1B).
To determine whether the c-secretase complex in PS1
transgenic mice is functional and active, we used an in vitro c-
secretase activity assay to assess the c-secretase enzymatic activity
in protein extracts derived from brains of PS1 transgenic mice.
Interestingly, c-secretase activity at both the Ab40 (Fig 1C) and
Ab42 cleavage site in brain extracts of PS1 transgenic mice
increased ,150% as compared to control mice, corroborating the
increase in protein levels of components of the c-secretase complex
observed in the brains. Consistent with our previous studies
[34,35], c-secretase activities in brains of Nct
+/2 mice were
reduced ,50% as compared with that of wild type mice (Fig. 1C).
These results establish that elevated levels of PS1 alone in the brain
of mice is sufficient to increase the level and enzymatic activity of
mature c-secretase complex in vivo.
While both PS1 and PS2 can form functional c-secretase
complex, it has been reported that the specific activity of PS1-
containing c-secretase is higher than that of PS2- containing
complex in vitro [36]. Exogenous expression of human PS1 replaces
both the endogenous PS1 and PS2, thus most c-secretase in the
PS1
wt transgenic mice are human PS1 containing c-secretase
complex. While we observed a significant increase of c-secretase
activity in PS1
wt mice, it is possible that the increased c-secretase
activity in PS1
wt transgenic mice is due to relative abundance of
PS1-containing c-secretase complex. To examine whether over-
expression of PS1 can increase the levels of active c-secretase
complex, we used a well characterized c-secretase transition-state
analogue inhibitor based probe (compound 4) [37] to quantify the
active fraction of c-secretase in vivo. Biotin labeled compound 4 can
specifically bind to the active c-secretase complex, thus active c-
secretase can be captured using streptavidin-labeled bead [37].
Membrane proteins were extracted using buffer containing
CHAPSO and the levels of PS1 and Nct in unbounded fractions
and affinity captured fractions of membrane protein extracts were
subjected to immunoblot analysis using antisera against Nct, PS1-
NTF and PS1-CTF. We found that ,70% of CHAPSO extracted
c-secretase complex can be captured by the compound-4, while
another membrane-bound secretase, BACE1, was not captured by
compound 4 (Fig. 1D), which confirmed that compound 4 is a
specific and high affinity inhibitor of c-secretase. Comparing the
levels of Nct and PS1 in the affinity captured fraction of PS1
wt
transgenic with that of non-transgenic control mice, we found that
the levels of Nct in affinity-captured fraction of PS1
wt mice
increased by more than 130% (Fig. 1D and 1E). These data
further support our view that overexpression of PS1 alone in the
brain increase the protein level of mature c-secretase complex and
enzymatic activity of c-secretase in vivo.
While our studies demonstrate that overexpression of PS1 can
significantly increase the level of mature c-secretase in the brain, it
is not clear whether such an increase is derived from neuronal or
non-neuronal cells. Since Ab is generated from sequential cleavage
of APP by b- and c-secretase and b-secretase (BACE1) is
abundantly expressed in neurons [38], the magnitude of Ab
secretion will be dependent on the level of c-secretase in neuronal
cells. To determine whether overexpression of PS1 can upregulate
the level of c-secretase in neurons, we isolated primary neuronal
and non-neuronal cells from brains of PS1 transgenic and wild
type embryos (at embryonic day 17) and assessed the levels of c-
secretase in these cells. The purity of our neuronal cultures was
determined using the neuron specific marker, b-tubulin III
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cultures derived from PS1 transgenic mice, the levels of Nct were
significantly increased (Fig. 2A and 2B), indicating that the
overexpression of PS1 alone is sufficient to increase the level of c-
secretase in either neuron or non-neuronal cells.
To examine the effects of upregulation of c-secretase in PS1
transgenic mice on generation of Ab and Ab amyloidosis, we
crossed the PS1 mice with a mouse model of amyloidosis, APP
swe
transgenic mice [39], to generate APP
swe;PS1
wt mice. Although no
Ab deposits were detected in the brains of 9 month-old
APP
swe;PS1
wt or APP
swe mice, ELISA analysis showed an ,30%
increase in the level of Ab40 in brains of APP
swe;PS1
wt mice as
compared to that of APP
swe mice (Fig. 3A, p,0.05), indicating
that upregulation of PS1 alone is sufficient to increase the
generation of Ab in brains of mice. To determine whether such
increase in c-secretase activity would accelerate amyloid
deposition, serial brain sections of 22 month-old APP
swe;PS1
wt
mice were stained with antibodies against Ab (6E10) or against
ubiquitin. Interestingly, greater amount of Ab plaques were
observed in brain sections of APP
swe;PS1
wt mice as compared to
that of APP
swe mice (Figs. 3D). Since the levels of APP in
APP
swe;PS1
wt mice is identical to that of APP
swe mice (Fig. 3E), the
elevation of Ab deposition is likely due to an increase in levels of
c-secretase in brains of PS1
wt mice. To quantify the levels of Ab
deposition, we used both filter trap and unbiased stereology
approaches to assess the amyloid burden in the brains of these
transgenic mice. We observed not only an ,2 fold increase of
aggregated Ab (Fig. 3B and 3C), but importantly, a correspond-
ing elevation of amount of Ab plaques (Fig. 3F) in the brains of
APP
swe;PS1
wt mice as compared to those of APP
swe mice. These
Figure 1. Increase of c-secretase activity in brains of PS1 mice. (A) Protein extracts (20 mg each) from brains of PS1 transgenic (lanes 1–3) and
non-transgenic mice (lanes 4–6) were immunoblotted with anti-sera specific to Nct, PS1-CTF, PEN2, PS2-CTF, or Actin. (B) Quantification of signals of
Nct, Pen-2, and PS2-CTF in protein blots by Image J program. The signal density was normalized using Actin signals derived from the same blot. (C) In
vitro c-secretase assay of brain extracts of wild type, PS1 transgenic, and Nct
+/2 mice. The data were average from 4 samples. (D) The CHAPSO
solubilized membrane proteins from wild type and PS1 transgenic mice were incubated with Compound 4 followed by precipitation with
streptavidin-coupled beads. Solubilized membranes before ligand addition (Input: 10% of total), captured fraction (Capture: 20% of total) of the
affinity ligand and the corresponding supernatants after capture (Unbound: 7.5% of total) were analyzed by Western blot using antisera specific to
Nct, PS1-CTF, PS1-NTF, or BACE1. (E) Quantification of signals of Nct levels from in protein blots by Image J program. The signal density was
normalized using BACE1 signals derived from the same blot.
doi:10.1371/journal.pone.0028179.g001
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increase the activity of c-secretase and deposition of Ab in the
brain and thus suggest that such increase of c-secretase activity
may confer risk in development of AD.
To further establish that overexpression of PS1 alone could
increase the level of c-secretase in the brain, we examined the
effects of overexpression of a variety of fAD-linked PS1 mutants in
mice. We first examined the protein levels of c-secretase in
transgenic mice that overexpress PS1DE9 and PS1-A246E
(Fig. 4A). Consistent with our observation in wild type PS1
transgenic mice, mice expressing PS1 mutants also exhibit
significant increase in the level of c-secretase complex in the
brains. The levels of several components of c-secretase (PS1, Nct,
PEN2) in PS1DE9 were similar as compared with those of PS1
transgenic mice, while the levels of components in PS1-A246E
mice were higher than those of PS1 transgenic mice (Fig. 4B),
which is consistent with previous reports [40]. Surprisingly, the
increase in levels of c-secretase components in the brains of
PS1DE9 and PS1-A246E mice did not lead to significant increase
in cleavage activity at the Ab40 site (Fig. 4C). Rather, the c-
secretase activity at the Ab40 site in brains of PS1-A246E mice
were 2–3 folds lower than that of wild type PS1 mice (Fig. 4C) and
Ab40 site cleavage activity observed in PS1DE9 mice was even
lower than that of non-transgenic mice (Fig. 4C). In parallel, we
assessed the cleavage activity at the Ab42 site in brain extracts
derived from these mice (Figure 4D). Interestingly, the activity at
the Ab42 site of c-secretase in PS1-A246E mice was significantly
higher than that of PS1 and non-transgenic mice (Fig. 4D). c-
Secretase activity in brains of PS1DE9 mice was similar to that of
non-transgenic mice. These findings indicate that the c-secretase
complex containing mutant PS1 is less active than that comprised
of wild type PS1, especially with respect to the cleavage activity at
the Ab40 site. However, whereas the ratio of Ab40/Ab42 activity
in PS1 mice was identical to that of non-transgenic mice, this ratio
was significantly decreased in both PS1DE9 and PS1-A246E mice
(Fig. 4E). These observations are consistent with the view that c-
secretase containing fAD-linked PS1 mutants elevate the relative
cleavage activity at the Ab42 site as compared to the Ab40 site
[39].
To compare the effects of mutant PS1 on Ab deposition with
that of wild type PS1, we crossed PS1DE9 mice with the APP
swe
mice to generate PS1DE9;APP
swe mice and assessed the Ab
amyloidosis in their brains. As anticipated, we observed that the
Ab burden in the brains of PS1DE9;APP
swe mice was significantly
higher than that of the APP
swe mice or PS1
wt;APP
swe mice (Fig. 4F
and 4G). These results are consistent with the idea that the relative
ratio of Ab42/Ab40 is a critical determinant for Ab deposition in
the brain [39].
Discussion
Since c-secretase is a key enzyme for the generation of Ab
peptides, understanding how c-secretase contributes to the
development of AD has been a major focus in the field. Mutations
in PS1 and PS2 have been identified in some rare cases of early
onset FAD [6–9]. These mutations increase the relative levels of
Ab42 [39], a more amyloidogenic and toxic form of Ab.I n
contrast, that increases in level of c-secretase accelerate the
production of Ab to elicit the Ab associated pathology would
provide a molecular mechanism for increasing the risk for AD.
Duplications of APP [10] in cases of AD is an example of such a
mechanism in which risk for AD is elevated through the increased
production of Ab. However, no genetic association between
increased level of c-secretase and higher risk of AD has been
reported. Furthermore, it is unknown as to how expression and
accumulation of c-secretase is regulated in the brain. It is well
recognized that the subunit assembly of c-secretase complex is
tightly regulated such that excess subunits like PS or PEN2, which
are not recruited into stable complexes are rapidly degraded.
Therefore, deletion of any component of the c-secretase leads to
the disassembly of the c-secretase complex. In contrast, cell culture
studies showing that levels of c-secretase can only be elevated by
increased expression of all four components has fueled the idea
that c-secretase would be more amenable to mechanisms that
down-regulates its levels than those that up-regulates it. For
example, a mutation that reduces expression of one of the four
components is predicted to decrease the level of c-secretase.
However, even polymorphism occurring in three of the four genes
Figure 2. Increase of c-secretase in primary neurons and non-neuronal cells derived from PS1 mice. (A) Protein extracts (20 mg each)
from primary neuronal and non-neuronal cultures derived from brains of PS1 and non-transgenic control mice were immunoblotted with anti-sera
specific to Nct, PS1-CTF, b-Tubulin III or Actin. (B) Quantification of Nct signals in protein blot of primary neuronal and non-neuronal cell extracts by
Image J program. The signal density was normalized using Actin signals derived from the same blot.
doi:10.1371/journal.pone.0028179.g002
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variants occurring simultaneously in all four genes encoding
components of the c-secretase may up-regulate its activity. The
realization that c-secretase is an essential enzymes for not only the
processing of APP, but also required for processing a growing list
of type I transmembrane proteins in a process called ‘‘regulated
intramembrane proteolysis’’ [41] indicates that maintenance of a
stable level of c-secretase is essential for the normal function of
organisms. Surprisingly, the studies described herein demonstrate
that increased expression of PS1 alone is sufficient to increase the
c-secretase activity and to elevate deposition of Ab in vivo,
indicating that alteration of a single component of c-secretase is
sufficient to elevate the level of c-secretase. While the clinical
relevance of our finding is still unclear, our observation also
suggests that increase in levels of c-secretase could be a potential
risk factor in AD. Although no association between risk of AD and
elevated levels of c-secretase has been documented in cases of AD,
increased levels in PS1 has been reported in senescence-
accelerated mice (SAMP8); it is possible that increased levels of
PS1 may lead to aberrant accumulation of Ab and loss of memory
in these mice [42].
Although we showed increased expression of PS1 is sufficient to
elevate c-secretase in vivo, it appears that increased expression of
Nct and Aph-1 does not elevate the level of c-secretase [43]. While
the effects of overexpressing PEN2 on the levels of c-secretase has
not been tested in vivo, the fact that the active center of c-secretase
complex resides within the PS subunit [22] would support the idea
that PS is the limiting factor that governs the assembly of c-
secretase in vivo. Interestingly, in cells lacking either Nct, Aph-1 or
Pen-2 [24,25,44], PS1 consistently appears to be the least stable
subunit as compared to other components. In contrast, without
PS, the amount of Aph1-Nct pre-complex is not significantly
affected in cells, although only immature form of Nct remains.
That PEN-2 is less stable than Nct or Aph-1 but more stable than
PS as remnants of Pen2 still can be detected in PS or Nct null cells
would support the notion that alterations in levels of PS1 should
have the most dramatic impact on the levels of c-secretase in vivo.
While the increase of c-secretase elevated the production of Ab
in mouse brains of PS1 mice, the amyloid burden was only
modestly increased. In parallel, the level of c-secretase in the fAD-
linked mutants PS1-A246 and PS1-DE9 mice can also be
increased. Interestingly, the c-secretase complex containing PS1-
A246E or PS1-DE9 mutant exhibited a drastic reduction in level of
c-secretase activity at the Ab40 site as compare to that of wild type
PS1 mice. Instead, relative levels for Ab42 processing were
increased as compared to that of the wild type PS1 mice whose
Ab42/40 ratio remained constant and consequently, accelerated
the amyloid burden in brains of PS1-DE9 mice. Our findings are
consistent with the notion that Ab42 is more toxic and readily
form Ab aggregates in the brain [39].
Figure 3. Increase in generation and deposition Ab in the brains of APP
swe;PS1 mice. (A) ELISA analysis of Ab40 peptides in the protein
extracts of brains of PS1 and non-transgenic control mice. The data were average +/2 SEM from 5 mice for each genotype. (B) Sagittal brain sections
(10 mm) of hippocampus area of 22-months old APP
swe;PS1 and APP
swe female mice. The Ab plaques were visualized by immunostaining with
antibodies specific to ubiquitin and Ab peptides (6E10). (C) Quantitative analysis of the levels of Ab aggregation in the brains of APP
swe;PS1 and APP
swe
mice at 22 months of age by filter trap assay. (D) Quantification of the signals of Ab aggregations in the filter trap assay using Image J program. (E)
Analysis of Ab deposition using unbiased stereology in the hippocampus of 22-months old APP
swe;PS1 (n=6) and APP
swe (n=10) female mice.
doi:10.1371/journal.pone.0028179.g003
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e28179Figure 4. Overexpression of FAD linked PS1 mutants increases the level of c-secretase in the brain. (A) Protein extracts (20 mg each) from
brains of PS1DE9 (lanes 1, 2), PS1-A246E (lanes 3, 4), PS1wt (lanes 5, 6) and non-transgenic mice (lanes 7–9) were immunoblotted with anti-sera specific
to Nct, PS1-NTF, PS1-CTF, PEN2, SOD-1 or Actin. (B) Quantification of signals of Nct, PEN2 and SOD-1 in protein blots of mutant and wild type PS1 and
non-transgenic control mice by Image J program. The signal density was normalized using Actin signal derived from the same blot. (C) In vitro c-
secretase assay of Ab40 cleavage in brain extracts of PS1DE9, PS1-A246E, PS1
wt and non-transgenic control mice. The data represent averages +/- SEM
from 4 mice for each genotype. (D) In vitro c-secretase assay of Ab42 cleavage in brain extracts of PS1DE9, PS1-A246E, PS1
wt and non-transgenic
control mice. The data represent averages +/2 SEM from 4 mice for each genotype. (E) The ratio of Ab40 and Ab42 cleavage activity in brain extracts
Expressing PS1 Elevates c-Secretase Activity
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e28179In summary, our data support the view that overexpression of
PS1 in vivo is sufficient to increase the generation and deposition
of Ab in the brain. Importantly, this unexpected finding strongly
implicates that upregulation of c-secretase could contribute to
increased risk of AD, especially in late onset sporadic AD.
Materials and Methods
Animals and cell lines
PS1(wt), PS1DE9, PS1A246E, and APP
swe mice were generated
as described previously [33,45]. PS1(wt) and PS1DE9, mice were
crossed with APP
swe mice to generate PS1wt;APP
swe and
PS1DE9;APP
swe mice. Animal housing and experimental protocols
were approved by the Animal Care and Use Committee of the
Johns Hopkins University (Protocol # MO09M243).
Affinity Capture of Endogenous c-Secretase
The affinity capture of active c-secretase was performed using a
procedure modified from that described previously [37]. In short,
100 mg CHAPSO-solubilized membrane proteins were incubated
for 2 h at 37uC in 50 mM PIPES, pH 7.0, 150 mM KCl, 5 mM
CaCl2, 5 mM MgCl2, and protease inhibitors in 0.5% (v/v)
CHAPSO with 20 nM biotinylated affinity probe (compound 4),
which is modified from a potent transition state analog of c-
secretase (L458) [37]. 250 ml (10 mg/mL) of streptavidin-coupled
magnetic beads (Dynal, Invitrogen) was added to the reaction and
incubated overnight at 4uC. Captured complexes were washed five
times with TBST buffer (Tris-buffered saline containing 0.1% (v/
v) Tween 20) and eluted with 2X SDS sample buffer. Samples
were resolved by SDS-PAGE and transferred to a polyvinylidene
difluoride membrane. PS1 and Nct were detected by protein
blotting using antiserum against PS1-NTF, PS1-CTF, and Nct.
The levels of BACE1 served as a loading control. In all cases,
protein blots shown are representatives of three or more
experiments.
Primary Cortical Neuronal and Non-neuronal Cells
Mouse primary neuronal cultures were obtained from cerebral
cortices of E18 embryos in a procedure modified from that
described previously [46]. In Short, brains were collected from
E18 PS1 transgenic or non-transgenic embryos and kept in ice-
cold Hanks’ balanced salt solution (HBSS). The dissected cortices
were minced, digested with an enzyme solution containing 10U of
papain (Sigma) and 10 mg/ml DNase I (Sigma) for 20 minutes,
and cells were mechanically dissociated in culture medium with
pipettes. Cells were counted and plated onto poly-L-lysine and
laminin coated six-well plates in Neurobasal medium supplement-
ed with 2% B27, 0.5 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin (all from Invitrogen). Medium was
replaced with fresh warm medium two hours later. Four days
after plating, 2.5 mM cytosine arabinoside (Ara-C; Sigma) was
added to eliminate proliferating astrocytes in the cultures. After 2
days of Ara-C exposure, the medium was changed once before the
cultures were subjected to further analysis. To derive non-
neuronal cells (astrocytes, microglia, and oligodendrocytes),
dissected cortices from the brains were minced on 35-mm petri
dishes on ice. To separate the cells, the minced tissues were
suspended in 750 ml 0.25% trypsin/EDTA containing 1 mg/ml
DNase I and incubated at 37uC for 15 min. Cells were centrifuged
for 5 min at 3006g at room temperature and the cell pellets were
dissociated in 5 ml of MEM containing 20% FBS.
Immunoblot and Antibodies
Immediately after euthanasia, mouse brain tissues were
dissected and proteins were extracted with TEPER buffer (Pierce
Chemical Co., Rockford, IL) containing complete protease
inhibitor cocktail (Roche, Indianapolis, IN). The protein concen-
trations in the supernatants were determined by the BCA method
(Pierce Chemical Co., Rockford, IL) and equal amount of protein
lysates resolved on 4–20% Tris-Glycine SDS PAGE gels,
transferred to polyvinylidene difluoride (PVDF) (Invitrogen,
Carlsbad, CA) membranes, and probed with following antibodies:
anti-Nicastrin [24]; antisera specific for PS1 [47], anti-PEN-2 [48],
and anti-Aph-1aL antibody (Covance Inc, Princeton, NJ). Blots
were probed using monoclonal antibody against actin and rabbit
anti-b-tubulinIII antisera (Sigma) were used as loading control.
Immunoblots were developed using enhanced chemiluminescence
method (Millipore Corp. MA).
In vitro c-secretase activity assay
The c-secretase activity of mouse brains were performed as
described previously [49]. After mouse brain membranes were
extracted in buffer A (50 mM Mes, pH 6.0/5 mM MgCl2/5 mM
CaCl2/150 mM KCl) with 16complete protease inhibitor mixture
(Boehringer Mannheim), 8 mg of membrane protein was incubated
with APP recombinant substrate (1 mM) in the presence of 0.25%
CHAPSO in buffer B (50 mM Pipes, pH 7.0/5 mM MgCl2/
5 mM CaCl2/150 mM KCl) at 37uC. The reactions were stopped
by adding RIPA (150 mM NaCl/1.0% NP-40/0.5% sodium
deoxycholate/0.1% SDS/50 mM Tris HCl, pH 8.0) and assayed
with G2-10 antibody, which recognizes the C-terminus of Ab40 by
ECL.
Filter Trap Assay
Cellulose acetate membranes with 0.2 mm pore size (OE66,
Schleicher & Schuell, Keene, NH) were used to trap the
aggregates containing Ab from the brain lysate [50]. Briefly,
mouse brains were weighed and then homogenized in 10 volumes
of PBS (pH 7.4) containing a protease inhibitor cocktail (Roche,
Indianapolis, IN). Homogenates were centrifuged at 3,000 rpm for
5 min at 4uC in a microcentrifuge. The protein concentrations in
the supernatants were determined by the BCA method (Pierce
Chemical Co., Rockford, IL). Before filtering, the samples were
diluted with PBS (100–200 mL) and adjusted to a final concentra-
tion of 1% SDS. After filtering, using a 96-well dot-blot apparatus
(Bio-Rad Laboratories, Hercules, CA), the membranes were
washed twice with 500 mL of PBS (pH 7.4) per well. Proteins
trapped by the filter were detected by rabbit anti-Ab antiserum
(Invitrogen, South San Francisco, CA) following conditions used
for immunoblotting analysis.
Ab ELISA Assay
To measure the Ab levels in vivo, the brains of APP
swe;PS1 and
APP
swe mice were dissected on ice, and homogenized in PBS buffer
containing 1% triton X-100 and complete protease inhibitor
of PS1DE9, PS1-A246E, PS1
wt and non-transgenic control mice. (F) Sagittal brain sections (10 mm) of 22-months old APP
swe;PS1DE9 female mice. The Ab
plaques were visualized by immunostaining with antibodies specific to ubiquitin and Ab peptides (6E10). (G) Analysis of Ab deposition using
unbiased stereology in brain sections of 22-months old APP
swe;PS1DE9 (n=5), APP
swe;PS1 (n=6), and APP
swe (n=10) female mice. The data represent
averages +/2 SEM from each genotype.
doi:10.1371/journal.pone.0028179.g004
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30 min, the supernatants containing soluble Ab peptides were
collected for assay. The concentrations of total protein extracts
were determined by the BCA method (Pierce Chemical Co.,
Rockford, IL). Ab40 levels were measured using a quantitative
sandwich ELISA kit (Invitrogen, South San Francisco, CA) that
specifically detects human Ab.
Histology and Immunohistochemical Analysis
For histological and immunohistochemical analysis of Ab
amyloidosis, mice were perfused with 4% PFA in PBS. Brains
were removed, embedded in paraffin, sectioned and processed.
Sections were analyzed immunohistochemically by the peroxidase-
antiperoxidase method using antibodies specific for: Ab
(6E10)(Signet Laboratories, Inc. Dedham, MA) and ubiquitin
(Dako Cooperation, Carpinteria, CA).
Measurement of amyloid plaques in mouse brain by
unbiased stereology
To assess the Ab plaque load, one half of the sagitally bisected
mouse brain was immersion fixed in 4% of PFA and embedded in
paraffin. The brains were sectioned at 10 mm and sections were
selected at 8-section intervals for analysis using a light microscope
interfaced with a Stereo Investigator (MicroBrightfield, Inc.). The
quantitative analysis was based on area fraction of ubiquitin
immunoreactivity as described previously [51].
Statistical analysis
All data were analyzed statistically by student’s t-test or
ANOVA. In all tests, the level of significance was at p,0.05.
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